4
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 5 , 6 , 8 , 9 , 2 , 4 , 10 , 11 , 2 , 3 , 13 , 14 , 15 , 1 , 16 , 5 , 7 , 17 , 18 , 19 , 10 , 19 , 2 , 3 , 10 , 9 , 2 , 3 , 4 , 1 , 2 , 3 , 19 , 9 , 20 , 15 , 14 , 21 , 10 , 2 , 3 , 4 , 2 , 3 , 2 , 3 , 9 , 15 , 10 , 14 , 15 , 7 , 17 , 18 , 15 , 9 , 22 , 23
      ChemRxiv
      ChemRxiv

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We present a supercomputer-driven pipeline for in-silico drug discovery using enhanced sampling molecular dynamics (MD) and ensemble docking. Ensemble docking makes use of MD results by docking compound databases into representative protein binding-site conformations, thus taking into account the dynamic properties of the binding sites. We also describe preliminary results obtained for 23 systems involving eight proteins of the proteome of SARS-CoV-2. The MD involves temperature replica exchange enhanced sampling, making use of massively-parallel supercomputing to quickly sample the configurational space of protein drug targets. Using the Summit supercomputer at the Oak Ridge National Laboratory, more than 1 ms of enhanced sampling MD can be generated per day. We have ensemble docked repurposing databases to ten configurations of each of the 23 SARS-CoV-2 systems using AutoDock Vina. We also demonstrate that using Autodock-GPU on Summit, it is possible to perform exhaustive docking of one billion compounds in under 24 hours. Finally, we discuss preliminary results and planned improvements to the pipeline, including the use of quantum mechanical (QM), machine learning, and AI methods to cluster MD trajectories and rescore docking poses.

          Related collections

          Most cited references153

          • Record: found
          • Abstract: not found
          • Article: not found

          GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Remdesivir for the Treatment of Covid-19 — Final Report

            Abstract Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. Results A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). Conclusions Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

              A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world1-3. Here, to better understand the initial step of infection at an atomic level, we determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor4. Structural analysis identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses1-3,5. The epitopes of two SARS-CoV antibodies that target the RBD are also analysed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.
                Bookmark

                Author and article information

                Journal
                ChemRxiv
                ChemRxiv
                chemrxiv
                ChemRxiv
                ChemRxiv
                2573-2293
                29 July 2020
                : 10.26434/chemrxiv.12725465.v1
                Affiliations
                [1 ]School of Physics, Georgia Institute of Technology, Atlanta, GA 30332
                [2 ]UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, TN, 37830
                [3 ]The University of Tennessee, Knoxville. Department of Biochemistry & Cellular and Molecular Biology, 309 Ken and Blaire Mossman Bldg. 1311 Cumberland Avenue Knoxville, TN, 37996
                [4 ]Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN, 37996
                [5 ]Computer Science and Mathematics Division, Oak Ridge National Lab, Oak Ridge, TN 37830
                [6 ]The University of Alabama in Huntsville, Department of Biological Sciences. 301 Sparkman Drive, Huntsville, AL 35899
                [7 ]Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
                [8 ]Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
                [9 ]Computational Science Initiative, Brookhaven National Laboratory, Upton, NY 11973
                [10 ]Biosciences Division, Oak Ridge National Lab, Oak Ridge, TN 37830
                [11 ]Department of Physical and Chemical Sciences, University of L’Aquila, I-67010 L’Aquila, Italy
                [13 ]University of Kentucky, Division of Biomedical Informatics, College of Medicine, UK Medical Center MN 150, Lexington KY, 40536
                [14 ]Scripps Research, La Jolla, CA, 92037
                [15 ]National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830
                [16 ]HPC Engineering, Amazon Web Services, Seattle, WA 98121
                [17 ]Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831
                [18 ]Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee, Knoxville, TN 37996
                [19 ]NVIDIA Corporation, Santa Clara, CA 95051
                [20 ]Data Science and Learning Division, Argonne National Lab, Lemont, IL 60439
                [21 ]Jubilee Development, Cambridge MA 02139
                [22 ]Department of Biological Sciences, New York City College of Technology, The City University of New York (CUNY), Brooklyn, NY 11201
                [23 ]CNR Institute of Nanoscience, I-41125 Modena, Italy
                Article
                12725465
                10.26434/chemrxiv.12725465
                7668744
                33200117
                547ce082-94b0-476d-8d72-db1ecb07c473

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

                History
                Categories
                Article

                Comments

                Comment on this article